The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial
- PMID: 23769413
- PMCID: PMC3819406
- DOI: 10.1016/j.brs.2013.04.009
The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial
Abstract
Background: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) over several weeks is an FDA approved treatment for major depression. Although rTMS is generally safe when administered using the FDA guidelines, there are a number of side effects that can make it difficult for patients to complete a course of rTMS. Many patients report that rTMS is painful, although patients appear to accommodate to the initial painfulness. The reduction in pain is hypothesized to be due to prefrontal stimulation and is not solely explained by accommodation to the stimulation.
Methods: In a recent 4 site randomized controlled trial (using an active electrical sham stimulation system) investigating the antidepressant effects of daily left dorsolateral prefrontal rTMS (Optimization of TMS, or OPT-TMS), the procedural painfulness of TMS was assessed before and after each treatment session. Computerized visual analog scale ratings were gathered before and after each TMS session in the OPT-TMS trial. Stimulation was delivered with an iron core figure-8 coil (Neuronetics) with the following parameters: 10 Hz, 120% MT (EMG-defined), 4 s pulse train, 26 s inter-train interval, 3000 pulses per session, one 37.5 min session per day. After each session, procedural pain (pain at the beginning of the TMS session, pain toward the middle, and pain toward then end of the session) ratings were collected at all 4 sites. From the 199 patients randomized, we had usable data from 142 subjects for the initial 15 TMS sessions (double-blind phase) delivered over 3 weeks (142 × 2 × 15 = 4260 rating sessions).
Results: The painfulness of real TMS was initially higher than that of the active sham condition. Over the 15 treatment sessions, subjective reports of the painfulness of rTMS (during the beginning, middle and end of the session) decreased significantly 37% from baseline in those receiving active TMS, with no change in painfulness in those receiving sham. This reduction, although greatest in the first few days, continued steadily over the 3 weeks. Overall, there was a decay rate of 1.56 VAS points per session in subjective painfulness of the procedure in those receiving active TMS.
Discussion: The procedural pain of left, prefrontal rTMS decreases over time, independently of other emotional changes, and only in those receiving active TMS. These data suggest that actual TMS stimulation of prefrontal cortex maybe related to the reduction in pain, and that it is not a non-specific accommodation to pain. This painfulness reduction softly corresponds with later clinical outcome. Further work is needed to better understand this phenomenon and whether acute within-session or over time painfulness changes might be used as short-term biomarkers of antidepressant response.
Trial registration: ClinicalTrials.gov NCT00149838.
Keywords: Clinical trial; Depression; OPT-TMS; Pain; Sham; TMS; Transcranial magnetic stimulation.
Copyright © 2013 Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Decreasing procedural pain over time of left prefrontal rTMS for depression: initial results from the open-label phase of a multi-site trial (OPT-TMS).Brain Stimul. 2009 Apr;2(2):88-92. doi: 10.1016/j.brs.2008.09.001. Brain Stimul. 2009. PMID: 20161310 Free PMC article. Clinical Trial.
-
A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients.Brain Stimul. 2014 May-Jun;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. Epub 2014 Mar 19. Brain Stimul. 2014. PMID: 24731434 Clinical Trial.
-
EEG synchronized left prefrontal transcranial magnetic stimulation (TMS) for treatment resistant depression is feasible and produces an entrainment dependent clinical response: A randomized controlled double blind clinical trial.Brain Stimul. 2023 Nov-Dec;16(6):1753-1763. doi: 10.1016/j.brs.2023.11.010. Epub 2023 Dec 2. Brain Stimul. 2023. PMID: 38043646 Free PMC article. Clinical Trial.
-
Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) In the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials.Depress Anxiety. 2015 Mar;32(3):193-203. doi: 10.1002/da.22339. Epub 2015 Feb 13. Depress Anxiety. 2015. PMID: 25683231 Review.
-
[Therapeutic application of repetitive transcranial magnetic stimulation for major depression].Seishin Shinkeigaku Zasshi. 2012;114(11):1231-49. Seishin Shinkeigaku Zasshi. 2012. PMID: 23367835 Review. Japanese.
Cited by
-
Repetitive transcranial magnetic stimulation focusing on patients with neuropathic pain in the upper limb: a randomized sham-controlled parallel trial.Sci Rep. 2024 May 23;14(1):11811. doi: 10.1038/s41598-024-62018-x. Sci Rep. 2024. PMID: 38782994 Free PMC article. Clinical Trial.
-
A randomized sham-controlled trial of high-dosage accelerated intermittent theta burst rTMS in major depression: study protocol.BMC Psychiatry. 2024 Jan 8;24(1):28. doi: 10.1186/s12888-023-05470-9. BMC Psychiatry. 2024. PMID: 38191370 Free PMC article.
-
A transdiagnostic review of safety, efficacy, and parameter space in accelerated transcranial magnetic stimulation.J Psychiatr Res. 2022 Aug;152:384-396. doi: 10.1016/j.jpsychires.2022.06.038. Epub 2022 Jun 28. J Psychiatr Res. 2022. PMID: 35816982 Free PMC article. Review.
-
Deep rTMS of the insula and prefrontal cortex in smokers with schizophrenia: Proof-of-concept study.Schizophrenia (Heidelb). 2022 Feb 25;8(1):6. doi: 10.1038/s41537-022-00224-0. Schizophrenia (Heidelb). 2022. PMID: 35217662 Free PMC article.
-
Pain trajectories of dorsomedial prefrontal intermittent theta burst stimulation versus sham treatment in depression.BMC Neurol. 2020 Aug 20;20(1):311. doi: 10.1186/s12883-020-01881-3. BMC Neurol. 2020. PMID: 32819321 Free PMC article. Clinical Trial.
References
-
- Borckardt JJ, Smith AR, Hutcheson K, et al. Reducing pain and unpleasantness during repetitive transcranial magnetic stimulation. J ECT. 2006;22(4):259–264. - PubMed
-
- O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biological Psychiatry. 2007;62(11):1208–1216. - PubMed
-
- George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507–516. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical